CorMedix Inc. (CRMD)
NGM · Healthcare · Biotechnology
$8.74
-2.46%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$685.7M
Shares Outstanding
78.5M
P/S (TTM)
1.7x
P/E (TTM)
4.1x
Exchange
NGM
Currency
USD
About CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 39.7M | 104.3M | 128.6M | 127.4M |
| Gross Profit | 37.9M | 93.1M | 107.3M | 105.1M |
| Operating Income | 19.5M | 51.3M | 59.1M | 63.7M |
| Net Income | 19.8M | 108.6M | 14.0M | 38.6M |
| Diluted EPS | $0.28 | $1.26 | $0.16 | $0.43 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 65K | 0.00 | 43.5M | 311.7M |
| Gross Profit | 62K | 0.00 | 40.3M | 275.7M |
| Operating Income | -30.6M | -49.0M | -22.4M | 150.1M |
| Net Income | -29.7M | -46.3M | -17.9M | 163.1M |
| Diluted EPS | $-0.74 | $-0.91 | $-0.30 | $2.04 |